Drug Profile
NXD 2858
Alternative Names: NXD-2858; Spheron targeting agentLatest Information Update: 18 Apr 2011
Price :
$50
*
At a glance
- Originator Nymox Pharmaceutical Corporation
- Class Antidementias; Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 16 Feb 2006 This compound is still in active development
- 25 Aug 2004 This compound is still in active development
- 02 Oct 2001 This compound is still in active development